Otilonium bromide

Otilonium bromide
Clinical data
Trade names	Spasmoctyl 40, Doralin
AHFS/Drugs.com	International Drug Names
ATC code	A03AB06 (WHO) ;
Identifiers
	IUPAC name N,N-Diethyl-N-methyl-2-(4-[2-(octyloxy)benzamido]benzoyloxy)ethanaminium bromide;
PubChem CID	72092;
ChemSpider	65077 ;
UNII	21HN3N72PV;
KEGG	D07083 ;
CompTox Dashboard (EPA)	DTXSID0046357 ;
ECHA InfoCard	100.043.128
Chemical and physical data
Formula	C29H43BrN2O4
Molar mass	563.57 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCCCCOC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)OCC[N+](C)(CC)CC.[Br-];
	InChI InChI=1S/C29H42N2O4.BrH/c1-5-8-9-10-11-14-22-34-27-16-13-12-15-26(27)28(32)30-25-19-17-24(18-20-25)29(33)35-23-21-31(4,6-2)7-3;/h12-13,15-20H,5-11,14,21-23H2,1-4H3;1H ; Key:VWZPIJGXYWHBOW-UHFFFAOYSA-N ;
	(what is this?) (verify)

Otilonium bromide is an antimuscarinic and calcium channel blocker used to relieve spasmodic pain of the gut, especially in irritable bowel syndrome.^[1]

Medical uses

A pooled analysis of three clinical trials suggest that otilonium is more effective than placebo for the treatment of irritable bowel syndrome.^[2]

Pharmacology

Otilinium binds to both muscarinic receptors and tachykinin NK₂ receptors.^[3] It has been shown to inhibit L-type and T-type calcium channels, actions which may contribute to or determine its effects in the gut.^[4]^[5]

When taken orally, very little of the drug is absorbed into the rest of the body,^[6] which means that most of its actions remain confined to the gastrointestinal system.

References

^ "Dismox" (PDF). Archived from the original (PDF) on 4 March 2016.
^ Clavé, P; Tack, J (March 2017). "Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis". Therapeutic advances in gastroenterology. 10 (3): 311–322. doi:10.1177/1756283X16681708. PMC 5305018. PMID 28246548.
^ Evangelista, S (1999). "Otilonium bromide: a selective spasmolytic for the gastrointestinal tract". The Journal of international medical research. 27 (5): 207–22. doi:10.1177/030006059902700501. PMID 10689627.
^ Martin, MT; Hove-Madsen, L; Jimenez, M (April 2004). "Otilonium bromide inhibits muscle contractions via L-type calcium channels in the rat colon". Neurogastroenterology & Motility. 16 (2): 175–83. doi:10.1111/j.1365-2982.2004.00518.x. PMID 15086871.
^ Strege, PR; Sha, L; Beyder, A; Bernard, CE; Perez-Reyes, E; Evangelista, S; Gibbons, SJ; Szurszewski, JH; Farrugia, G (May 2010). "T-type Ca(2+) channel modulation by otilonium bromide". American Journal of Physiology. Gastrointestinal and Liver Physiology. 298 (5): G706-13. doi:10.1152/ajpgi.00437.2009. PMC 2867415. PMID 20203058.
^ Shin, BS; Kim, JJ; Kim, J; Hu, SK; Kim, HJ; Hong, SH; Kim, HK; Lee, HS; Yoo, SD (January 2008). "Oral bioavailability and enterohepatic recirculation of otilonium bromide in rats". Archives of pharmacal research. 31 (1): 117–24. doi:10.1007/s12272-008-1129-2. PMID 18277617.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

[1] "Dismox" (PDF). Archived from the original (PDF) on 4 March 2016.

[2] Clavé, P; Tack, J (March 2017). "Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis". Therapeutic advances in gastroenterology. 10 (3): 311–322. doi:10.1177/1756283X16681708. PMC 5305018. PMID 28246548.

[3] Evangelista, S (1999). "Otilonium bromide: a selective spasmolytic for the gastrointestinal tract". The Journal of international medical research. 27 (5): 207–22. doi:10.1177/030006059902700501. PMID 10689627.

[4] Martin, MT; Hove-Madsen, L; Jimenez, M (April 2004). "Otilonium bromide inhibits muscle contractions via L-type calcium channels in the rat colon". Neurogastroenterology & Motility. 16 (2): 175–83. doi:10.1111/j.1365-2982.2004.00518.x. PMID 15086871.

[5] Strege, PR; Sha, L; Beyder, A; Bernard, CE; Perez-Reyes, E; Evangelista, S; Gibbons, SJ; Szurszewski, JH; Farrugia, G (May 2010). "T-type Ca(2+) channel modulation by otilonium bromide". American Journal of Physiology. Gastrointestinal and Liver Physiology. 298 (5): G706-13. doi:10.1152/ajpgi.00437.2009. PMC 2867415. PMID 20203058.

[6] Shin, BS; Kim, JJ; Kim, J; Hu, SK; Kim, HJ; Hong, SH; Kim, HK; Lee, HS; Yoo, SD (January 2008). "Oral bioavailability and enterohepatic recirculation of otilonium bromide in rats". Archives of pharmacal research. 31 (1): 117–24. doi:10.1007/s12272-008-1129-2. PMID 18277617.

[1]

[2]

[3]

[4]

[5]

[6]